Mesna Injection

Mesna Injection

Product Name:Mesna injection, Uromitexan

Nombre del Producto: Mesna inyección

Specification: 4ml 0.4g

Package: 4ml:0.4g/vial

Standard: State Standard


Mesna injection


A colorless transparent liquid. 



MESNEX is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.

Limitation of Use

MESNEX is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia.


Dosage and administration

MESNEX may be given on a fractionated dosing schedule of three bolus intravenous injections as outlined below.

MESNEX injection is given as intravenous bolus injections in a dosage equal to 20% of the ifosfamide dosage weight by weight (w/w) at the time of ifosfamide administration and 4 and 8 hours after each dose of ifosfamide. The total daily dose of MESNEX is 60% of the ifosfamide dose. The recommended dosing schedule is outlined below in Table 1.

Table 1: Recommended Intravenous Dosing Schedule


Ifosfamide 1.2 g/m² - -

MESNEX Injection1 240 mg/m² 240 mg/m² 240 mg/m²

1The dosing schedule should be repeated on each day that ifosfamide is administered. When the dosage of ifosfamide is increased or decreased, the ratio of MESNEX to ifosfamide should be maintained.


Side Effect 

The following are discussed in more detail in other sections of the labeling.

Hypersensitivity Reactions 

Dermatological Toxicity 

Benzyl Alcohol Toxicity

Laboratory Test Interferences 

Use in Patients with a History of Adverse Reactions to Thiol Compounds 


Hypersensitivity Reactions

MESNEX may cause systemic hypersensitivity reactions, includinganaphylaxis. These reactions may include fever, cardiovascular symptoms (hypotension, tachycardia), acute renal impairment, hypoxia, respiratory distress, urticaria, angioedema, laboratory signs of disseminated intravascular coagulation, hematological abnormalities, increased liver enzymes, nausea, vomiting, arthralgia, and myalgia. These reactions may occur with the first exposure or after several months of exposure. Monitor for signs or symptoms. Discontinue MESNEX and provide supportive care.

Dermatologic Toxicity

Drug rash with eosinophilia and systemic symptoms and bullous and ulcerative skin and mucosal reactions, consistent with Stevens-Johnson syndrome or toxic epidermal necrolysis have occurred. MESNEX may cause skin and mucosal reactions characterized by urticaria, rash, erythema,pruritus, burning sensation, angioedema, periorbital edema, flushing and stomatitis. These reactions may occur with the first exposure or after several months of exposure. Discontinue MESNEX and provide supportive care.

Hot Tags: mesna injection manufacturers, suppliers, price, pharmaceutical, mesna 400mg


Subscribe to our email list
Sign up with your name and email to get the latest proway updates, exclusive access to promotions, sales events, pre-order sales & more!
Connect with Sundent Pharm Group
Become our fan, follow us & subscribe for the latest updates and deals
QR Code
  • About Us
  • Products
  • News
  • Knowledge
  • Contact Us
  • Feedback
  • Copyright © Sundent Pharm Group All rights reserved.